| First Author | Xavier S | Year | 2017 |
| Journal | Am J Physiol Renal Physiol | Volume | 312 |
| Issue | 3 | Pages | F516-F532 |
| PubMed ID | 28052876 | Mgi Jnum | J:273995 |
| Mgi Id | MGI:6295217 | Doi | 10.1152/ajprenal.00604.2016 |
| Citation | Xavier S, et al. (2017) Pericytes and immune cells contribute to complement activation in tubulointerstitial fibrosis. Am J Physiol Renal Physiol 312(3):F516-F532 |
| abstractText | We have examined the pathogenic role of increased complement expression and activation during kidney fibrosis. Here, we show that PDGFRbeta-positive pericytes isolated from mice subjected to obstructive or folic acid injury secrete C1q. This was associated with increased production of proinflammatory cytokines, extracellular matrix components, collagens, and increased Wnt3a-mediated activation of Wnt/beta-catenin signaling, which are hallmarks of myofibroblast activation. Real-time PCR, immunoblots, immunohistochemistry, and flow cytometry analysis performed in whole kidney tissue confirmed increased expression of C1q, C1r, and C1s as well as complement activation, which is measured as increased synthesis of C3 fragments predominantly in the interstitial compartment. Flow studies localized increased C1q expression to PDGFRbeta-positive pericytes as well as to CD45-positive cells. Although deletion of C1qA did not prevent kidney fibrosis, global deletion of C3 reduced macrophage infiltration, reduced synthesis of C3 fragments, and reduced fibrosis. Clodronate mediated depletion of CD11bF4/80 high macrophages in UUO mice also reduced complement gene expression and reduced fibrosis. Our studies demonstrate local synthesis of complement by both PDGFRbeta-positive pericytes and CD45-positive cells in kidney fibrosis. Inhibition of complement activation represents a novel therapeutic target to ameliorate fibrosis and progression of chronic kidney disease. |
